Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 23 — AAIC preview with Eisai deputy CCO Michael Irizarry

Biotechnology
Simon Wentworth
6 July 2023
podcast-23-large

More on this story...

Pharmaceutical
Data disaster casts cloud over BioXcel's Alzheimer's agitation results
29 June 2023
Pharmaceutical
Otsuka tees up Japanese filing for brexpiprazole in Alzheimer's agitation
28 June 2023
Biotechnology
The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's
17 July 2023
Pharmaceutical
BRIEF—Eisai divest two drugs to Kaken
29 March 2024


Companies featured in this story

More ones to watch >


Today's issue

Nektar sells its PEGylation reagent manufacturing business
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Pharmaceutical
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Biotechnology

Nektar sells its PEGylation reagent manufacturing business
5 November 2024
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Frits van Alphen gets Memo CDO job
4 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze